Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.41 |
| ▸ | BCL2 | P10415 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 2/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 5/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.39 |
| ▸ | ITGAV | P06756 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25630192 | 1.00 | PPARD (0.45) | PPARDHTR2CPTPN1BCL2MCL1 | |
| SCHEMBL25630091 | 0.87 | HTR2C (0.62) | PPARDHTR2CPTPN1HTR2APARP15 | |
| SCHEMBL31494780 | 0.87 | HTR2C (0.62) | PPARDHTR2CPTPN1HTR2APARP15 | |
| SCHEMBL25421677 | 0.84 | MEN1 (0.49) | PPARDHTR2CNPC1RAB9A | |
| SCHEMBL25421675 | 0.84 | MEN1 (0.49) | PPARDHTR2CNPC1RAB9A | |
| SCHEMBL30488430 | 0.84 | MEN1 (0.49) | PPARDHTR2CNPC1RAB9A | |
| SCHEMBL30488439 | 0.84 | MEN1 (0.49) | PPARDHTR2CNPC1RAB9A | |
| SCHEMBL25421751 | 0.82 | HTR2C (0.47) | PPARDHTR2CBCL2MCL1HTR2A | |
| SCHEMBL30488390 | 0.82 | HTR2C (0.47) | PPARDHTR2CBCL2MCL1HTR2A | |
| SCHEMBL25421755 | 0.82 | HTR2C (0.47) | PPARDHTR2CBCL2MCL1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051276-A1 | ARYLOXY PSYCHOPLASTOGENS AND USES THEREOF | DELIX THERAPEUTICS, INC. | 2025-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051276-A1 | ARYLOXY PSYCHOPLASTOGENS AND USES THEREOF | GRIN2A, GRIN2C, GAP43 | PPARD 393/4885HTR2C 79/4885PTPN1 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.